globus medical inc. - GMED

GMED

Close Chg Chg %
90.46 0.28 0.31%

Open Market

90.74

+0.28 (0.31%)

Volume: 1.86M

Last Updated:

Jan 17, 2025, 3:59 PM EDT

Company Overview: globus medical inc. - GMED

GMED Key Data

Open

$90.90

Day Range

89.34 - 91.04

52 Week Range

49.33 - 91.44

Market Cap

$12.36B

Shares Outstanding

136.17M

Public Float

112.93M

Beta

1.19

Rev. Per Employee

N/A

P/E Ratio

136.97

EPS

$0.67

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.19M

 

GMED Performance

1 Week
 
4.28%
 
1 Month
 
9.89%
 
3 Months
 
24.64%
 
1 Year
 
60.65%
 
5 Years
 
70.36%
 

GMED Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About globus medical inc. - GMED

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

GMED At a Glance

Globus Medical, Inc.
2560 General Armistead Avenue
Audubon, Pennsylvania 19403-5214
Phone 1-610-930-1800 Revenue 1.57B
Industry Medical Specialties Net Income 122.87M
Sector Health Technology 2023 Sales Growth 53.345%
Fiscal Year-end 12 / 2024 Employees 5,000
View SEC Filings

GMED Valuation

P/E Current 136.476
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 49.716
Price to Sales Ratio 3.895
Price to Book Ratio 1.817
Price to Cash Flow Ratio 25.087
Enterprise Value to EBITDA 17.635
Enterprise Value to Sales 3.897
Total Debt to Enterprise Value 0.085

GMED Efficiency

Revenue/Employee 313,695.20
Income Per Employee 24,574.60
Receivables Turnover 3.107
Total Asset Turnover 0.438

GMED Liquidity

Current Ratio 4.882
Quick Ratio 2.72
Cash Ratio 1.32

GMED Profitability

Gross Margin 61.797
Operating Margin 12.869
Pretax Margin 10.545
Net Margin 7.834
Return on Assets 3.431
Return on Equity 4.205
Return on Total Capital 2.719
Return on Invested Capital 3.868

GMED Capital Structure

Total Debt to Total Equity 13.037
Total Debt to Total Capital 11.533
Total Debt to Total Assets 10.248
Long-Term Debt to Equity 12.726
Long-Term Debt to Total Capital 11.258
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Globus Medical Inc. - GMED

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
789.04M 958.10M 1.02B 1.57B
Sales Growth
+0.47% +21.43% +6.76% +53.34%
Cost of Goods Sold (COGS) incl D&A
234.29M 257.75M 281.46M 599.21M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
62.87M 69.87M 68.25M 144.73M
Depreciation
46.04M 51.34M 50.52M 93.70M
Amortization of Intangibles
16.83M 18.53M 17.73M 51.03M
COGS Growth
+20.90% +10.01% +9.20% +112.89%
Gross Income
554.75M 700.35M 741.38M 969.27M
Gross Income Growth
-6.23% +26.25% +5.86% +30.74%
Gross Profit Margin
+70.31% +73.10% +72.48% +61.80%
2020 2021 2022 2023 5-year trend
SG&A Expense
414.86M 471.18M 504.98M 767.42M
Research & Development
60.10M 63.03M 72.86M 124.01M
Other SG&A
354.76M 408.15M 432.12M 643.41M
SGA Growth
+0.01% +13.58% +7.17% +51.97%
Other Operating Expense
- - - -
-
Unusual Expense
28.46M 57.22M 8.45M 68.71M
EBIT after Unusual Expense
111.43M 171.95M 227.95M 133.14M
Non Operating Income/Expense
14.47M 8.45M 15.07M 32.25M
Non-Operating Interest Income
13.95M 9.30M 14.23M 20.13M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
125.90M 180.41M 243.02M 165.39M
Pretax Income Growth
-33.72% +43.30% +34.71% -31.94%
Pretax Margin
+15.96% +18.83% +23.76% +10.54%
Income Tax
23.61M 31.22M 52.85M 42.52M
Income Tax - Current - Domestic
26.56M 45.12M 73.33M 96.69M
Income Tax - Current - Foreign
991.00K 3.74M 1.84M 4.08M
Income Tax - Deferred - Domestic
(3.97M) (15.80M) (19.57M) (52.64M)
Income Tax - Deferred - Foreign
30.00K (1.85M) (2.76M) (5.61M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
102.28M 149.19M 190.17M 122.87M
Minority Interest Expense
- - - -
-
Net Income
102.28M 149.19M 190.17M 122.87M
Net Income Growth
-34.10% +45.86% +27.47% -35.39%
Net Margin Growth
+12.96% +15.57% +18.59% +7.83%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
102.28M 149.19M 190.17M 122.87M
Preferred Dividends
- - - -
-
Net Income Available to Common
102.28M 149.19M 190.17M 122.87M
EPS (Basic)
1.0376 1.481 1.8928 1.0865
EPS (Basic) Growth
-33.72% +42.73% +27.81% -42.60%
Basic Shares Outstanding
98.58M 100.73M 100.47M 113.09M
EPS (Diluted)
1.013 1.4398 1.8527 1.0719
EPS (Diluted) Growth
-33.43% +42.13% +28.68% -42.14%
Diluted Shares Outstanding
100.97M 103.62M 102.64M 114.63M
EBITDA
202.76M 299.04M 304.65M 346.58M
EBITDA Growth
-11.64% +47.48% +1.88% +13.76%
EBITDA Margin
+25.70% +31.21% +29.78% +22.10%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 97.846
Number of Ratings 17 Current Quarters Estimate 0.777
FY Report Date 03 / 2025 Current Year's Estimate 3.439
Last Quarter’s Earnings 0.76 Median PE on CY Estimate N/A
Year Ago Earnings 2.988 Next Fiscal Year Estimate 3.928
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 15 13
Mean Estimate 0.78 0.87 3.44 3.93
High Estimates 0.85 0.93 3.60 4.33
Low Estimate 0.73 0.82 3.27 3.53
Coefficient of Variance 4.04 3.89 2.65 4.95

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 8
OVERWEIGHT 2 2 2
HOLD 5 4 5
UNDERWEIGHT 1 2 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Globus Medical Inc. - GMED

Date Name Shares Transaction Value
Nov 26, 2024 David D. Davidar Director 523,041 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 44,458,485.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director 130,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $43.58 per share 5,665,400.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director 50,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $43.77 per share 2,188,500.00
Nov 26, 2024 Daniel T. Lemaitre Director 625 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Lemaitre Director 1,722 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Lemaitre Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.02 per share 0.00
Nov 26, 2024 Daniel T. Lemaitre Director 1,097 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.05 per share 71,359.85
Nov 26, 2024 Daniel T. Lemaitre Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 0.00
Nov 26, 2024 Daniel T. Lemaitre Director 13,278 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.05 per share 863,733.90
Nov 26, 2024 David D. Davidar Director 165,967 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 14,107,195.00
Nov 26, 2024 David D. Davidar Director 516,275 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 43,883,375.00
Nov 26, 2024 David D. Davidar Director 172,713 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 14,680,605.00
Jul 16, 2024 Leslie V. Norwalk Director 16,419 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70 per share 1,149,330.00
May 15, 2024 Daniel T. Lemaitre Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2024 Kelly G. Huller SVP, GC, Corporate Secretary 7,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.9 per share 186,750.00
Mar 6, 2024 Kelly G. Huller SVP, GC, Corporate Secretary 3,115 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $53.79 per share 167,555.85
Mar 6, 2024 Kelly G. Huller SVP, GC, Corporate Secretary N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.53 per share 0.00

Globus Medical Inc. in the News